JP2024095709A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024095709A5 JP2024095709A5 JP2024050685A JP2024050685A JP2024095709A5 JP 2024095709 A5 JP2024095709 A5 JP 2024095709A5 JP 2024050685 A JP2024050685 A JP 2024050685A JP 2024050685 A JP2024050685 A JP 2024050685A JP 2024095709 A5 JP2024095709 A5 JP 2024095709A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- oncolytic hsv
- immune
- oncolytic
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1700350.0A GB201700350D0 (en) | 2017-01-09 | 2017-01-09 | Altered virus |
| GB1700350.0 | 2017-01-09 | ||
| PCT/GB2018/050048 WO2018127713A1 (en) | 2017-01-09 | 2018-01-09 | Altered virus |
| JP2019537074A JP7520511B2 (ja) | 2017-01-09 | 2018-01-09 | 改変ウイルス |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537074A Division JP7520511B2 (ja) | 2017-01-09 | 2018-01-09 | 改変ウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024095709A JP2024095709A (ja) | 2024-07-10 |
| JP2024095709A5 true JP2024095709A5 (https=) | 2024-10-18 |
| JP7813310B2 JP7813310B2 (ja) | 2026-02-12 |
Family
ID=58463943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537074A Active JP7520511B2 (ja) | 2017-01-09 | 2018-01-09 | 改変ウイルス |
| JP2024050685A Active JP7813310B2 (ja) | 2017-01-09 | 2024-03-27 | 改変ウイルス |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537074A Active JP7520511B2 (ja) | 2017-01-09 | 2018-01-09 | 改変ウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12059444B2 (https=) |
| EP (2) | EP3565568B1 (https=) |
| JP (2) | JP7520511B2 (https=) |
| KR (1) | KR20190104055A (https=) |
| CN (1) | CN110198724B (https=) |
| AU (1) | AU2018205763B2 (https=) |
| BR (1) | BR112019013215A2 (https=) |
| CA (1) | CA3049496A1 (https=) |
| DK (1) | DK3565568T3 (https=) |
| ES (1) | ES3038026T3 (https=) |
| GB (1) | GB201700350D0 (https=) |
| IL (1) | IL267949B2 (https=) |
| MX (2) | MX2019008146A (https=) |
| WO (1) | WO2018127713A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3778881A1 (en) | 2016-01-08 | 2021-02-17 | Replimune Limited | Modified oncolytic virus |
| RU2749050C2 (ru) | 2016-01-27 | 2021-06-03 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| US12310999B2 (en) | 2017-04-28 | 2025-05-27 | Merck Sharp & Dohme Corp. | Biomarkers for cancer therapeutics |
| AU2018306455A1 (en) | 2017-07-26 | 2020-02-27 | Virogin Biotech Canada Ltd | Oncolytic viral vectors and uses thereof |
| DK3661954T3 (da) | 2017-08-03 | 2022-04-19 | Amgen Inc | Interleukin-21-muteiner og fremgangsmåder til behandling |
| MA50077A (fr) | 2017-09-08 | 2020-07-15 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆（苏州）医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
| CA3124690A1 (en) | 2018-12-27 | 2020-07-02 | Amgen Inc. | Lyophilized virus formulations |
| AU2020232264B2 (en) | 2019-03-05 | 2026-02-19 | Amgen Inc. | Use of oncolytic viruses for the treatment of cancer |
| TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
| CN113891747A (zh) * | 2019-05-15 | 2022-01-04 | 郑州威瑞生物技术有限公司 | 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 |
| CN110218707B (zh) * | 2019-05-29 | 2021-10-22 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| US20220162644A1 (en) * | 2019-05-29 | 2022-05-26 | Orbis Health Solutions, Llc | Delivery vectors and particles for expressing chimeric receptors and methods of using the same |
| AU2019462166A1 (en) * | 2019-08-16 | 2022-03-03 | Immvira Co., Limited | Pharmaceutical compositions comprising oncolytic herpes simplex virus for systemic administration |
| CN110982795B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种单纯疱疹病毒及其用途 |
| CN110982794B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种修饰的单纯疱疹病毒 |
| CN114075574A (zh) * | 2020-08-19 | 2022-02-22 | 广东东阳光药业有限公司 | 构建体、溶瘤病毒及其应用 |
| JP2026501236A (ja) * | 2022-12-20 | 2026-01-14 | ヤンセン バイオテツク，インコーポレーテツド | 腫瘍溶解性ウイルス及びその使用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| US6040169A (en) | 1991-01-31 | 2000-03-21 | Medical Research Council | Herpes simplex virus-1 deletion variants and vaccines thereof |
| ES2183811T3 (es) | 1992-03-31 | 2003-04-01 | Arch Dev Corp | Tratamiento de enfermedades tumorigenas con un hsv modificado. |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| WO1997012623A1 (en) | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| GB9700411D0 (en) * | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| EP1955703A1 (en) | 1999-11-12 | 2008-08-13 | Oncolytics Biotech Inc. | Viruses for the treatment of cellular proliferative disorders |
| DE60115600T2 (de) | 2000-01-21 | 2006-07-20 | Biovex Ltd. | Virusstämme für die onkolytische behandlung von krebs |
| CA2441663C (en) | 2001-03-27 | 2013-01-22 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
| GB0317511D0 (en) * | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| RU2007114111A (ru) | 2004-11-04 | 2008-12-10 | Пфайзер Продактс Инк. (Us) | Лечение рака молочной железы с помощью комбинации антитела против ctla4 и ингибитора ароматазы |
| EP1871806A2 (en) | 2005-03-08 | 2008-01-02 | Pharmacia & Upjohn Company LLC | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
| CN101495126B (zh) | 2005-06-23 | 2016-01-06 | 休斯顿大学 | Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途 |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| EP2307033A4 (en) | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS |
| CN102575227A (zh) | 2008-10-08 | 2012-07-11 | 英特瑞克斯顿股份有限公司 | 表达多种免疫调节剂的工程改造细胞及其应用 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| WO2011063309A1 (en) | 2009-11-20 | 2011-05-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| WO2011119925A2 (en) | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| WO2011118866A1 (ko) | 2010-03-26 | 2011-09-29 | 연세대학교 산학협력단 | 네트워크를 통한 심사요청 방법 |
| KR20130108371A (ko) | 2010-09-24 | 2013-10-02 | 온코스 테라퓨틱스 오와이 | 단클론 항―ｃｔｌａ－４ 항체를 암호화하는 종양분해 아데노바이러스 벡터 |
| FI20115914A7 (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| DK2806883T3 (da) | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| CA2877414A1 (en) * | 2012-07-30 | 2014-02-06 | Alex Wah Hin Yeung | Live and in-vivo tumor specified cancer vaccine system |
| JP6457940B2 (ja) | 2012-08-30 | 2019-01-23 | アムジエン・インコーポレーテツド | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 |
| US9789182B2 (en) * | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| EP2958592A1 (en) | 2013-02-22 | 2015-12-30 | F. Hoffmann-La Roche AG | Methods of treating cancer and preventing drug resistance |
| EA038981B1 (ru) | 2013-03-14 | 2021-11-17 | Икан Скул Оф Медсин Эт Маунт Синай | Вирусы болезни ньюкасла и их применение |
| WO2015032755A1 (en) | 2013-09-03 | 2015-03-12 | Medimmune Limited | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
| AU2014338864C1 (en) * | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
| CN106068326B (zh) * | 2013-10-28 | 2021-06-18 | 联邦高等教育系统-匹兹堡大学 | 溶瘤性hsv载体 |
| CA2931322A1 (en) | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| US10933106B2 (en) * | 2014-02-25 | 2021-03-02 | Deutsches Krebsforschungszentrum | RNA viruses for immunovirotherapy |
| MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| DK3169341T3 (da) * | 2014-07-16 | 2019-08-05 | Transgene Sa | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| AU2015289081B2 (en) | 2014-07-16 | 2020-02-06 | Transgene Sa | Combination of oncolytic virus with immune checkpoint modulators |
| US20160040186A1 (en) * | 2014-08-07 | 2016-02-11 | Xiaoyun Liu | Dna construct and method for transgene expression |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| CA2974529C (en) | 2015-01-23 | 2023-08-15 | Dreamwell, Ltd. | Automated mattress manufacturing process and apparatus |
| CN104987421A (zh) * | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| EP3778881A1 (en) * | 2016-01-08 | 2021-02-17 | Replimune Limited | Modified oncolytic virus |
| KR102211838B1 (ko) * | 2016-04-22 | 2021-02-03 | 임비라 컴퍼니 리미티드 | 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조 |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| US20210252135A1 (en) * | 2018-06-21 | 2021-08-19 | Replimune Limited | Treatment using oncolytic virus |
-
2017
- 2017-01-09 GB GBGB1700350.0A patent/GB201700350D0/en not_active Ceased
-
2018
- 2018-01-09 MX MX2019008146A patent/MX2019008146A/es unknown
- 2018-01-09 KR KR1020197023554A patent/KR20190104055A/ko not_active Ceased
- 2018-01-09 CN CN201880006355.8A patent/CN110198724B/zh active Active
- 2018-01-09 IL IL267949A patent/IL267949B2/en unknown
- 2018-01-09 CA CA3049496A patent/CA3049496A1/en active Pending
- 2018-01-09 US US16/466,612 patent/US12059444B2/en active Active
- 2018-01-09 BR BR112019013215-5A patent/BR112019013215A2/pt unknown
- 2018-01-09 DK DK18701924.5T patent/DK3565568T3/da active
- 2018-01-09 EP EP18701924.5A patent/EP3565568B1/en active Active
- 2018-01-09 ES ES18701924T patent/ES3038026T3/es active Active
- 2018-01-09 EP EP25186357.7A patent/EP4635984A3/en active Pending
- 2018-01-09 WO PCT/GB2018/050048 patent/WO2018127713A1/en not_active Ceased
- 2018-01-09 JP JP2019537074A patent/JP7520511B2/ja active Active
- 2018-01-09 AU AU2018205763A patent/AU2018205763B2/en active Active
-
2019
- 2019-07-05 MX MX2025002735A patent/MX2025002735A/es unknown
-
2024
- 2024-03-27 JP JP2024050685A patent/JP7813310B2/ja active Active
- 2024-07-10 US US18/769,170 patent/US20240358781A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024095709A5 (https=) | ||
| Rui et al. | Cancer immunotherapies: advances and bottlenecks | |
| Ferris | Immunology and immunotherapy of head and neck cancer | |
| US20230212531A1 (en) | Engineered virus | |
| JP7250185B2 (ja) | 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス | |
| JP2020503871A5 (https=) | ||
| JP2019500909A5 (https=) | ||
| JP2019501670A5 (https=) | ||
| JP2021529741A (ja) | がん治療 | |
| JP2020503342A (ja) | 免疫調節性腫瘍崩壊性アデノウイルスベクターならびに癌の処置のためのその産生および使用方法 | |
| JP2019501671A5 (https=) | ||
| CN110381997A (zh) | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 | |
| JP2021527694A5 (https=) | ||
| KR20240132482A (ko) | 항암 백시니아 바이러스와 관문 저해제 병용 요법 | |
| TWI851676B (zh) | 溶瘤病毒用於治療癌症之用途 | |
| JP2021518408A5 (https=) | ||
| Wang et al. | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? | |
| CN112020510A (zh) | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 | |
| Xu et al. | Enhanced cellular therapy: revolutionizing adoptive cellular therapy | |
| KR20240024048A (ko) | Nk 세포와 her2 표적 항체를 이용한 암 치료 방법 | |
| JP2022526942A (ja) | 癌のネオアジュバント療法における腫瘍溶解性ウイルスの使用 | |
| Tenesaca et al. | Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors | |
| JPWO2019243847A5 (https=) | ||
| JPWO2020036635A5 (https=) | ||
| US20220305100A1 (en) | Methods of vaccination and use of cd47 blockade |